Cannabidivarinic acid or CBDVA is an acid precursor to CBDV, which is a product of decarboxylation of CBDVA. From a chemical perspective, CBDVA shares a similar basic structure with other cannabinoids. It contains a propyl side chain and a resorcinol moiety, connected by a central alkylated benzene ring

Pharmacologically, CBDVA is believed to interact with the endocannabinoid system (ECS) in the human body. The ECS plays a crucial role in regulating various physiological processes, such as mood, pain sensation, appetite, and immune response. CBDVA is thought to interact with cannabinoid receptors, namely CB1 and CB2 receptors, as well as other non-cannabinoid receptors.

Although research on CBDVA is limited compared to other cannabinoids like CBD or THC, preliminary studies suggest potential therapeutic properties. It has been found to exhibit anti-inflammatory effects, indicating potential applications in conditions such as arthritis and inflammatory bowel disease. Furthermore, CBDVA may have anticonvulsant properties, suggesting it could be explored as a treatment option for epilepsy and seizure disorders.